Antibody-drug conjugate engineering: from design to efficacy and safety.

Ocana A, Espinosa JR, Alonso-Moreno C, Győrffy B, Tong H, Pandiella A

Open source

DOI
10.1038/s41392-026-03057-w
Published
2026 Sep 23
Container
Signal transduction and targeted therapy
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41392-026-03057-w,
  title = {Antibody-drug conjugate engineering: from design to efficacy and safety.},
  author = {Ocana A and Espinosa JR and Alonso-Moreno C and Győrffy B and Tong H and Pandiella A},
  year = {2026},
  journal = {Signal transduction and targeted therapy},
  doi = {10.1038/s41392-026-03057-w},
  url = {https://doi.org/10.1038/s41392-026-03057-w}
}

RIS

TY  - JOUR
TI  - Antibody-drug conjugate engineering: from design to efficacy and safety.
AU  - Ocana A
AU  - Espinosa JR
AU  - Alonso-Moreno C
AU  - Győrffy B
AU  - Tong H
AU  - Pandiella A
PY  - 2026
JO  - Signal transduction and targeted therapy
DO  - 10.1038/s41392-026-03057-w
UR  - https://doi.org/10.1038/s41392-026-03057-w
ER  - 

APA

A, O., JR, E., C, A., B, G., H, T., & A, P. (2026). Antibody-drug conjugate engineering: from design to efficacy and safety.. Signal transduction and targeted therapy. https://doi.org/10.1038/s41392-026-03057-w

Source records